Since 1982, the Japanese Society for Psoriasis Research has conducted annual epidemiological surveys of patients with psoriasis. Kawada et al. have reported data for 1982-2001 and Takahashi et al. have reported data for 2002 -2008 . The present study evaluated 9290 psoriatic cases according to age and sex (2009)(2010)(2011)(2012). The male : female ratio was 2.08:1 (6281 male patients [67.6%] to 3009 female patients [32.4%]). The most prevalent type was psoriasis vulgaris (85.6% of all cases), which was followed by psoriasis arthropathica (6.0%), psoriasis guttate acuta (3.2%), Zumbusch-type generalized pustular psoriasis (1.8%) and psoriasis erythroderma (1.5%). Psoriasis vulgaris was the most prevalent type for all ages, while psoriasis arthropathica and psoriasis guttate acuta were most prevalent among patients aged less than 65 years. The present survey detected an increased number of cases with comorbid diabetes and/or arthritis symptoms compared with the previous surveys. We found that treatments frequently involved topical corticosteroids (89.7% of cases) and vitamin D 3 ointments (78.0% of cases), with a notable increase in the use of vitamin D 3 ointments. Systemic treatments were used in 33.3% of cases, including cyclosporin (33.6%), etretinate (19.5%), methotrexate (8.6%), infliximab (11.4%), adalimumab (10.9%) and ustekinumab (6.2%). Phototherapy was used in 30.9% of cases. Although psoralen plus ultraviolet A therapy was the predominant phototherapy during previous studies, the present survey revealed that narrowband ultraviolet B therapy was used in 84.5% of phototherapy-treated cases. Thus, the present survey revealed major changes in treatment trends.
INTRODUCTION
Since 1982, the Japanese Society for Psoriasis Research (JSPR) has conducted annual epidemiological surveys of patients with psoriasis in partnership with multiple medical institutions throughout Japan. Kawada 
METHODS
The JSPR partners with medical institutions throughout Japan and uses its own questionnaire to perform annual surveys and collect data regarding newly registered psoriatic cases (from April of the previous year to March of the survey year). A total of 131 medical institutions participated in the surveys for the present study during 2009-2012 (87 university hospitals, 42
non-university hospitals and two private clinics). The survey items were participant characteristics (sex, age, family history, atopic diathesis and autoimmune disease), lifestyle habits (smoking and alcohol consumption), medical history (tonsillitis, stroke, cardiovascular disease, nephritis and hepatitis), type of psoriasis, disease severity, body surface area affected by psoriasis, complications (joint symptoms, nail involvement, mucous membrane involvement, pruritus and fever), comorbidities (diabetes mellitus, cardiovascular disease, cerebral vascular disorders, other cerebral vascular disorders, hypertension, hyperlipidemia, infection, tonsillitis and hyperuricemia) and exacerbating factors (stress, seasonal factors, infection, sun exposure, pregnancy, beta-blockers and interferon). The present study also evaluated the treatments that the patients had received (cyclosporin, etretinate, methotrexate, oral corticosteroids, infliximab, adalimumab, ustekinumab, topical corticosteroids, topical vitamin D 3 . Only data from completed surveys were included. During previous years, the data had been aggregated for all ages, although we examined data from patients who were less than 65 years old and 65 years and older starting in 2009 to evaluate the differences between younger and elderly patients. This study was supported by the JSPR.
RESULTS

Distributions according to age
The (Fig. 1 ).
Age at onset
The ages at disease onset were 0-9 years for 131 patients (1.8%; 65 boys [ 
Past history
The patients with psoriasis also had histories of tonsillitis (all ages, 5.8%; <65 years old, 7.3%; ≥65 years old, 2.1%), stroke (all ages, 4.1%; <65 years old, 1.6%; ≥65 years old, 9.8%), cardiovascular disease (all ages, 2.9%; <65 years old, 1.7%; ≥65 years old, 5.6%), nephritis (all ages, 3.1%; <65 years old, 3.0%; ≥65 years old, 3.5%) and hepatitis (all ages, 7.4%; <65 years old, 6.4%; ≥65 years old, 9.9%).
Lifestyle
Some patients with psoriasis consumed alcohol (all ages, 38.8%; <65 years old, 42.2%; ≥65 years old, 29.4%) and smoked (all ages, 46.0%; <65 years old, 48.2%; ≥65 years old, 40.0%).
Years
No. of patients and severe (all ages, 4.0%; <65 years old, 4.1%; ≥65 years old, 3.3%). Among generalized pustular psoriatic cases, the severities were mild (all ages, 13.0%; <65 years old, 19.2%; ≥65 years old, 9.2%), moderate (all ages, 32.1%; <65 years old, 23.2%; ≥65 years old, 46.2%) and severe (all ages, 54.9%; <65 years old, 57.6%; ≥65 years old, 44.6%). Among Zumbusch-type cases, the severities were mild (all ages, 11.2%; <65 years old, 12.9%; ≥65 years old, 7.8%), moderate (all ages, 28.6%; <65 years old, 20.8%; ≥65 years old, 45.1%) and severe (all ages, 59.9%; <65 years old, 66.3%; ≥65 years old, 47.1%). Among psoriasis erythroderma cases, the severities were mild (all ages, 1.5%; <65 years old, 0.0%; ≥65 years old, 4.3%), moderate (all ages, 11.8%; <65 years old, 12.5%; ≥65 years old, 10.6%) and severe (all ages, 86.7%; <65 years old, 87.5%; and ≥65 years old, 85.1%). Among localized pustular psoriatic cases, the severities were mild (all cases, 79.5%; <65 years old, 85.7%; ≥65 years old, 55.6%), moderate (all ages, 18.2%; <65 years old, 14.3%; ≥65 years old, 33.3%) and severe (all ages, 2.3%; <65 years old, 0.0%; ≥65 years old, 11.1%). Among pediatric psoriatic cases, the severities were mild (64.3%), moderate (21.4%) and severe (14.3%). Among other cases of psoriasis, the severities were mild (all ages, 71.4%; <65 years old, 74.5%; ≥65 years old, 65.2%), moderate (all ages, 23.0%; <65 years old, 19.6%; ≥65 years old, 30.4%) and severe (all ages, 5.4%; <65 years old, 5.9%; ≥65 years old, 4.4%) ( Tables 3,4) .
Types of psoriasis
Distributions of psoriatic lesions
The psoriatic lesions were located on the scalp (all ages, 7.9%; <65 years old, 8.1%; ≥65 years old, 7.4%), forehead (all ages, 4.1%; <65 years old, 4.4%; ≥65 years old, 3.5%), neck (all ages, 2.9%; <65 years, 3.0%; ≥65 years old, 2.7%), arms (all ages, 6.4%; <65 years old, 6.2%; ≥65 years old, 6.9%), hands (all ages, 4.5%; <65 years old, 4.5%; ≥65 years old, 4.4%), chest (all ages, 7.1%; <65 years old, 7.1%; ≥65 years old, 6.9%), abdomen (all ages, 6.8%; <65 years old, 6.7%; ≥65 years old, 7.1%), groin (all ages, 2.9%; <65 years old, 3.1%; ≥65 years old, 2.4%), back (all ages, 9.1%; <65 years old, 9.1%; ≥65 years old, 9.0%), buttocks (all ages, 6.8%; <65 years old, 6.6%; ≥65 years old, 7.4%), <65 years old, 8.5%; ≥65 years old, 3.8%), sun exposure (all ages, 1.3%; <65 years old, 1.5%; ≥65 years old, 0.8%), pregnancy (all ages, 0.0%), beta-blockers (all ages, 0.9%; <65 years old, 0.5%; ≥65 years old, 1.9%) and interferon (all ages, 0.7%; <65 years old, 0.6%; ≥65 years old, 0.9%) ( Table 7) .
Laboratory results
The patients subsequently decreased with age. Among female patients, the proportions increased gradually after the age of 20 years, peaked in the 50-59-and 60-69-year-old age groups, and subsequently decreased. Sinniah et al. 8 have
reported that the proportion of affected patients peaked in the 40-60-year-old age group for both sexes, and that younger and older age groups had relatively low proportions. In Taiwan, the proportion of affected patients peaked among 40-49-yearold men and among 50-59-year-old women, although a large number of affected cases was observed among 70-79-yearold patients. 6 Kubota et al. have reported that the proportion peaked among 60-69-year-old men and women. 9 In the present study, the peak proportion was observed approximately 10 years later, compared with the peak proportions in the 50-59-year-old age groups that were reported by Kawada et al.
1
and Takahashi et al. 2 This difference may be related to the increased average life expectancy, prolonged working life or later age at onset. Among men, the peak age at onset was 30-39 years (18.6%), which was followed by 60-69 years (17.0%) and 20-29 and 50-59 years (15.5%). Among women, the peak age at onset was 20-29 years (19.9%), which was followed by 50-59 years (15.0%) and 10-19 years (14.6%).
The most common type of psoriasis was psoriasis vulgaris (85.6%), which was followed by psoriasis arthropathica (6.0%), psoriasis guttate acuta (3.2%), Zumbusch-type psoriasis (1.8%) and psoriasis erythroderma (1.5%). Psoriasis vulgaris was relatively common in all age groups, while psoriasis arthropathica and psoriasis guttate acuta were more prevalent among patients who were less than 65 years old. Previous reports have indicated that psoriasis vulgaris was the most common type in the Iberian Peninsula (79.8%) 10 and Chile (71.9%). 9 The next most common type in both regions was guttate psoriasis, although the rate in the Iberian Peninsula was much lower (6.7%) 10 than that in Chile (17.7%). 9 In the present study, the rate of psoriasis arthropathica was 6.0%, which is noticeably higher than the rates in the reports by Kawada et 12 while the international rates of psoriasis arthropathica range from 4.7% to 42%. 5 The increase in the Japanese rate of psoriasis arthropathica may reflect the increasing number of psoriatic cases, the approval of biologic agents for treating psoriasis (which may motivate dermatologists to focus on the relationship between psoriasis and arthritis) and/or the increasing number of patients who complete periodic medical check-ups. In the present study, the severity distribution (mild : moderate : severe) for all psoriasis types was 2:1.5:1. In the USA, the severity distribution is 5.4:2.7:1.
13 Therefore, the severity ratios in Japan and the USA have similar ordinal relationships. However, the severity distributions in the present study varied among the different psoriasis types. For example, psoriasis vulgaris was most likely to be mild, psoriasis guttate acuta and psoriasis arthropathica were most likely to be moderate, and psoriatic erythroderma and Zumbusch-type psoriasis were most likely to be severe. Among the Zumbusch-type psoriatic cases, patients who were aged 65 years or older were most likely to have moderate disease severity and patients who were less than 65 years old were most likely to have severe disease. Similar results were observed for the other types of psoriasis.
The reported values for a family history of psoriasis vary widely throughout the world (2-91%), although relatively similar results have been reported for Spain (40.7%), the Iberian Peninsula (49.6%), Sweden (52%) and Japan (47.1%). 7 The present study revealed a relatively low rate of 6.4% (<65 years old, 7.4%; ≥65 years old, 3.6% Patients who were less than 65 years old were most likely to have had a father with psoriasis, and a large proportion of patients who were aged 65 years or older had a child with psoriasis. These results may be related to the fact that patients who are less than 65 years old include minors, unmarried adults and adults with no children, as well as the likelihood of having children increasing with age.
The most common region of onset was the knees (11.3%), which was followed by the elbows (10.7%), back (9.1%), scalp (7.9%), forehead (4.1%) and neck (2.9%). We did not observe any notable differences between the male and female patients. A study of Malaysian patients revealed that the most common region of onset was the upper limbs (53.0%), which was followed by the lower limbs (44.0%), trunk (15.9%), genital area (12.4%), and head and neck (11.8%). 8 Approximately one-half of the patients in the present study complained of pruritus, although Kawada et 7 The present study revealed a rate of 13.6%; which suggests that there has been a gradual increase over time in Japan. Furthermore, the rate of arthritis-related hand symptoms was especially high among patients who were less than 65 years old (16.3%). The present study revealed that 13.9% of the patients had diabetes mellitus (<65 years old, 10.6%; ≥65 years old, 22.4%), 5.2% had ischemic heart disease (<65 years old, 2.8%; ≥65 years old, 11.2%), 3.8% had cerebral infarction or other cerebral vascular disorders (<65 years old, 1.9%; ≥65 years old, 8.6%), 27.8% had hypertension (<65 years old, 20.0%; ≥65 years old, 47.1%) and 3.5% had tonsillitis (<65 years old, 4.5%; ≥65 years old, 0.8%). In the previous reports by Kawada et al. 1 and Takahashi et al., 2 the rates of diabetes mellitus were 7.0% and 11.1%, respectively, the rates of cardiovascular diseases were 4.2% and 8.2%, respectively, the rates of hypertension were 1.1% and 19.7%, respectively, and the rates of tonsillitis were 3.9% and 5.4%, respectively.
In Chile, the reported rates of diabetes mellitus and hypertension were 11.1% and 20.3%, 5 respectively, and the reported rates in the Iberian Peninsula were 8.3% and 20.2%, respectively. 9 Thus, the present survey revealed higher rates, compared with both domestic and foreign reports, which confirms the relationship between psoriasis and metabolic syndrome. 14 The most important exacerbating factor was stress (16.6%), which was followed by seasonal factors (13.3%) and infection (7.1%). Winter was the most common season for symptom exacerbation (63.2% of all seasonal cases) and was followed by spring (19.9%). Interestingly, patients who were aged 65 years and older were most likely to experience symptom exacerbation during the summer (13.7%). Kawada et al. 1 and
Takahashi et al. 2 reported that the stress rates were 6.4% and 14.4%, respectively, the seasonal factor rates were 9.7% and 11.0%, respectively, and the infection rates were 3.5% and 4.0%, respectively. Therefore, exacerbation from stress and infection appears to have increased in Japan. The prevalence of infections that we observed among less than 65-year-old patients may be related to the prevalence of tonsillitis among young people. Laboratory testing revealed relatively high numbers of cases with hyperuricemia, hyperlipidemia and CRP positivity. When we analyzed the data according to age, we did not observe any age-related differences in RF positivity, hyperuricemia, hyperlipidemia, high white blood cell counts or CRP positivity. However, patients who were less than 65 years old frequently exhibited ASLO elevation. Kadawa et al. 1 and Takahashi et al. 2 have reported hyperlipidemia rates of 11.6% and 34.6%, respectively, high white blood cell count rates of 7.0% and 14.3%, respectively, hyperuricemia rates of 4.3% and 20.0%, respectively, and elevated ASLO rates of 5.1% and 17.3%, respectively. Only Takahashi et al. reported the rate for RF positivity (9.3%). The findings of the present study indicate that the rates of hyperlipidemia and hyperuricemia are increasing. In the present study, most patients were receiving topical therapies (topical steroids, 89.7%; activated vitamin D 3 , 78.0%) and there were no age-related variations. In this context, tacalcitol was launched in 1993 and calcipotriol was launched in 2000, and these drugs were widely available during the study period. Thus, our findings indicate that vitamin D 3 became established as a standard topical therapy during the study period, as it was more common in the present study, compared with during Takahashi et al.'s study (59.7% of cases receiving vitamin D 3 ). In Taiwan, topical steroids were used in 98.4% of cases, whereas activated vitamin D 3 was only used in 25.1% of cases, which indicates that, unlike in Japan, steroids are the main topical therapy in Taiwan.
